Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for Treating Autoimmune Disorders, and Reagents Related Thereto

a technology for which is applied in the field of methods for treating autoimmune disorders and reagents related thereto, and can solve problems such as the potential for producing hypoglycemia, the increase of insulin deficiencies, and the further damage of cells

Inactive Publication Date: 2012-09-13
TRUSTEES OF TUFTS COLLEGE +1
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about improving treatment and prevention of autoimmune diseases in humans and animals. One aspect of the invention involves using a dipeptidylpeptidase IV (DPIV) inhibitor to treat these diseases. This inhibitor can reduce the immune response and affect the levels of hormones needed for tissue regeneration. Overall, this method can help to suppress the autoimmune response and promote tissue regeneration.

Problems solved by technology

Uncontrolled hyperglycemia can further damage the cells of the pancreas which produce insulin (the n-islet cells) and in the long term create greater insulin deficiencies.
Both agents have the potential for producing hypoglycemia as a side effect, reducing the blood glucose concentration to dangerous levels.
There is no generally applicable and consistently effective means of maintaining an essentially normal fluctuation in glucose levels in DM.
However, to date, there has been no cure for many autoimmune disorders, including type 1 diabetes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for Treating Autoimmune Disorders, and Reagents Related Thereto
  • Methods for Treating Autoimmune Disorders, and Reagents Related Thereto
  • Methods for Treating Autoimmune Disorders, and Reagents Related Thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of BoroProline

[0313]Referring to FIG. 1, the starting compound I is prepared essentially by the procedure of Matteson et al. (Organometallics 3:1284, 1984), except that a pinacol ester is substituted for the pinanediol ester. Similar compounds such as boropipecolic acid and 2-azetodine boronic acid can be prepared by making the appropriate selection of starting material to yield the pentyl and propyl analogs of compound I. Further, Cl can be substituted for Br in the formula, and other diol protecting groups can be substituted for pinacol in the formula, e.g., 2,3-butanediol and alphapinanediol.

[0314]Compound II is prepared by reacting compound I with [(CH3)O3Si]2N—Li+. In this reaction hexamethyldisilazane is dissolved in tetrahydrofuran and an equivalent of n-butyllithium added at −78° C. After warming to room temperature (20° C.) and cooling to −78° C., an equivalent of compound I is added in tetrahydrofuran. The mixture is allowed to slowly come to room temperature and...

example 2

Preparation of BoroProline-Pinacol

[0318]The intermediate, 4-Bromo-1-chlorobutyl boronate pinacol, was prepared by the method in Matteson et al. (Organometallics 3:1284, 1984) except that conditions were modified for large scale preparations and pinacol was substituted for the pinanediol protecting group.

[0319]3-bromopropyl boronate pinacol was prepared by hydrogenboronation of allyl bromide (173 ml, 2.00 moles) with catechol borane (240 ml, 2.00 moles). Catechol borane was added to allyl bromide and the reaction heated for 4 hours at 100° C. under a nitrogen atmosphere. The product, 3-bromopropyl boronate catechol (bp 95-102° C., 0.25 mm), was isolated in a yield of 49% by distillation. The catechol ester (124 g, 0.52 moles) was transesterified with pinacol (61.5 g, 0.52 moles) by mixing the component in 50 ml of THF and allowing them to stir for 0.5 hours at 0° C. and 0.5 hours at room temperature. Solvent was removed by evaporation and 250 ml of hexane added. Catechol was removed ...

example 3

Synthesis of BoroProline Peptides

[0323]General methods of coupling of N-protected peptides and amino acids with suitable side-chain protecting groups to H-boroProline-pinacol are applicable. When needed, side-chain protecting and N-terminal protecting groups can be removed by treatment with anhydrous HCl, HBr, trifluoroacetic acid, or by catalytic hydrogenation. These procedures are known to those skilled in the art of peptide synthesis.

[0324]The mixed anhydride procedure of Anderson et al. (J. Am. Chem. Soc. 89:5012, 1984) is preferred for peptide coupling. Referring again to FIG. 1, the mixed anhydride of an N-protected amino acid or a peptide is prepared by dissolving the peptide in tetrahydrofuran and adding one equivalent of N-methylmorpholine. The solution is cooled to −20° C. and an equivalent of isobutyl chloroformate is added. After 5 minutes, this mixture and one equivalent of triethylamine (or other sterically hindered base) are added to a solution of H-boroPro-pinacol di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumeaaaaaaaaaa
body weightaaaaaaaaaa
Login to View More

Abstract

The invention generally relates to improved methods for the treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease.

Description

FUNDING[0001]Work described herein was supported by funding from the National Institutes of Health. The United States Government has certain rights in the invention.BACKGROUND OF THE INVENTION[0002]The immune system can normally distinguish “self” from “non-self”. Some immune system cells (lymphocytes) become sensitized against “self” tissue cells, but are normally controlled by other lymphocytes. When the normal control process is disrupted, allowing lymphocytes to avoid suppression, or when there is an alteration in some body tissue so that it is no longer recognized by the immune system as “self”, autoimmune disorders develop. The mechanisms that cause disrupted control or tissue alterations are not well known. One theory holds that various microorganisms and drugs may trigger some of these changes, particularly in people with genetic predisposition to autoimmune disorders. There are a number of autoimmune diseases including, for example, multiple sclerosis (MS), rheumatoid arthr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/69A61K38/02A61P3/10A61K38/00A61BA61K31/40A61K31/401A61K38/04A61K38/05A61K38/24A61P1/00A61P5/14A61P7/00A61P13/12A61P17/00A61P19/02A61P19/04A61P21/04A61P25/00A61P29/00A61P31/18A61P37/00A61P37/02A61P37/08A61P43/00
CPCA61K31/40A61K38/005A61K31/69A61K31/401A61P1/00A61P1/04A61P1/18A61P3/10A61P5/14A61P7/00A61P13/12A61P17/00A61P19/02A61P19/04A61P21/04A61P25/00A61P29/00A61P31/18A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00
Inventor BACHOVCHIN, WILLIAM W.KUCHROO, VIJAY K.
Owner TRUSTEES OF TUFTS COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com